Last 45 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.00 | — | — | — | — | — | — | — | — | — | — | 0.05 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | 0.01 | — | 0.02 |
| — | — | — | — | — | — | — | — | — | — | -13.3% | — | +37.7% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -179.9% | -26.3% | -8.0% | -16.9% | -48.6% | — | — | — | — | -225.0% | -143.8% | — | -192.4% |
| — | — | — | — | — | — | — | — | — | -230.2% | -181.8% | — | -181.2% | |
| ROA | -72.1% | -13.2% | -3.7% | -7.3% | -14.2% | -74.1% | -192.6% | -156.2% | -95.0% | -46.4% | -49.9% | — | -24.9% |
| — | +82.2% | +98.1% | +95.3% | +85.1% | -59.7% | -285.8% | — | -281.4% | -69.8% | -35.5% | — | +43.3% | |
| ROIC | -172.5% | -7.1% | -10.3% | -12.0% | -43.1% | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 34.7% YoY to 0.19x, tightening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.15 | 0.09 | 0.06 | 0.08 | 0.15 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 0.15 | 0.19 | 0.19 | 0.16 | 0.15 | 0.29 | 0.58 | 0.44 | 0.95 | 0.95 | 1.53 | — | 1.15 |
| — | -34.7% | -66.7% | -63.4% | -84.3% | -69.4% | -62.2% | — | -17.5% | -17.5% | -59.0% | — | -39.9% | |
| Quick Ratio | 0.15 | 0.19 | 0.19 | 0.16 | 0.15 | 0.29 | 0.58 | 0.44 | 0.95 | 0.95 | 1.53 | — | 1.15 |
| — | -34.7% | -66.7% | -63.4% | -84.3% | -69.4% | -62.2% | — | -17.5% | -17.5% | -59.0% | — | -39.9% | |
| Interest Coverage | — | -18.38 | -62.38 | -64.09 | -34.64 | -42.42 | -146.06 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 45 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonAkari Therapeutics, Plc's current P/E is -0.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Akari Therapeutics, Plc's business trajectory between earnings reports.